Amazentis Overview

  • Founded
  • 2007
  • Status
  • Private
  • Employees
  • 17
  • Latest Deal Type
  • Series D
  • (In Progress)
  • Latest Deal Amount
  • $43M
Latest Deal Amount
  • Investors
  • 5

Amazentis General Information


Operator of a life science company intended to offer products targeting mitochondrial health for advanced nutrition. The company's services provide proprietary technology that mimics the effect of certain foods such as pomegranates to clean up damage in cellular powerhouses called mitochondria and creates an active lifestyle, enabling hospitals to manage specific health needs by optimizing the muscle functions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Primary Office
  • EPFL Innovation Park
  • Bâtiment C
  • 1015 Lausanne
  • Switzerland

Amazentis Timeline

Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amazentis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series D) 28-Sep-2021 $43M 000.00 In Progress Generating Revenue
4. Later Stage VC 02-Apr-2019 00.00 Completed Generating Revenue
3. Later Stage VC (Series C) 21-Mar-2018 00.00 00.00 000.00 Completed Generating Revenue
2. Later Stage VC 01-Aug-2015 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Amazentis’s complete valuation and funding history, request access »

Amazentis Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 000.00 000.00 00 000.00 00.00
To view Amazentis’s complete cap table history, request access »

Amazentis Patents

Amazentis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210210190-A1 Diagnostic method Pending 04-Nov-2019 000000000
JP-2021513994-A Process scale synthesis of urolithin a Pending 27-Feb-2018 0000000000
CA-3092106-A1 Process-scale synthesis of urolithin a Pending 27-Feb-2018 0000000000
AU-2019227733-A1 Process-scale synthesis of urolithin a Pending 27-Feb-2018 0000000000
US-20210198225-A1 Process-scale synthesis of urolithin a Pending 27-Feb-2018 C07D311/80

Amazentis Executive Team (5)

Name Title Board Seat Contact Info
Chris Rinsch Ph.D Co-Founder, Chief Executive Officer and Board Member
Federico Luna Chief Marketing & E-Commerce Officer
Patrick Aebischer MD Co-Founder & Chairman
Pierre Landolt Co-Founder & Board Member
Anurag Singh Ph.D Chief Medical Officer
To view Amazentis’s complete executive team members history, request access »

Amazentis Board Members (6)

Name Representing Role Since
Chris Rinsch Ph.D Amazentis Co-Founder, Chief Executive Officer and Board Member 000 0000
Eric Lohrer Self Board Member 000 0000
Odile Rundquist Ph.D Amazentis Board Member 000 0000
Patrick Aebischer MD Amazentis Co-Founder & Chairman 000 0000
Pierre Landolt Amazentis Co-Founder & Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Amazentis Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amazentis Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
frogVentures Venture Capital Minority 000 0000 000000 0
Nestlé Health Science Corporation Minority 000 0000 000000 0
ND Capital Venture Capital Minority 000 0000 000000 0
Gurnet Point Capital PE/Buyout Minority 000 0000 000000 0
EPFL Innovation Park Accelerator/Incubator 000 0000 000000 0
To view Amazentis’s complete investors history, request access »